2018, Number 1
<< Back Next >>
Rev Cub Med Int Emerg 2018; 17 (1)
DAWN Trial: increasing the therapeutic window for patients with cerebral infarction
Moscote-Salazar LR, Narváez-Rojas AR, Pacheco-Hernández A
Language: Spanish
References: 6
Page: 90-92
PDF size: 267.61 Kb.
ABSTRACT
Achieving the brain blood flow toward to survival areas is the principal objective in the ischemic stroke. DAWN trial was a controlled study with endovascular treatment during ischemic stroke. The prognosis of patients was better in the group treated with endovascular technique (48.6 %) in comparison with the control group (13.1 %) receiving medical standard treatment.
REFERENCES
Berkhemer OA, Fransen PSS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015;372:11-20
Navarrete P, Pina F, Rodríguez R, Murillo F, Jimenez D. Manejo inicial del ictus isquemico agudo. Med Intensiva. 2008;32: 431–43.
Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. DOI: 10.1056/NEJMoa1706442.
Brott T, Adams HP, Olinger CP, Marler JR, Barsan WG, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989; 20: 864–870
Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a metaanalysis of individual patient data from five randomised trials. Lancet 2016; 387:1723-31.
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischaemic stroke. N Engl J Med. 1995;333:1581–7
Full text